Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck U.S. Restructuring Not To Blame For Q1 Sales Drop, Execs Say

Executive Summary

Merck is assuring analysts that its massive commercial restructuring continues to benefit, not stifle, product growth, as company executives reported lower-than-expected sales and earnings April 21

You may also be interested in...



Merck Gets A Headache: Unexpectedly Halts Development Of Migraine Drug

Meanwhile, the drug maker hopes to file a different drug, talcagepant, to treat acute migraines, but has yet to say when that will happen.

Merck Gets A Headache: Unexpectedly Halts Development Of Migraine Drug

Meanwhile, the drug maker hopes to file a different drug, talcagepant, to treat acute migraines, but has yet to say when that will happen.

Merck/Schering Merger Brings A Partial Solution For Sales & Marketing

When Merck and Schering Plough executives promoted their proposed $41 billion merger March 9, they forecasted compounded annual earnings growth in the high single digits over each of the next several years. But they paid scant attention to top-line growth

Related Content

Topics

UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel